Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$1.77 USD
+0.01 (0.57%)
Updated Apr 26, 2024 03:46 PM ET
After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SONN 1.77 +0.01(0.57%)
Will SONN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SONN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SONN
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
SONN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beat the Market the Zacks Way: Vertiv, Costco, Sonnet BioTherapeutics in Focus
Other News for SONN
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
RNLX, ASLN and SONN among pre-market losers
Sonnet BioTherapeutics announces safety data from Phase 1b/2a trial of SON-080
Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective